Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK. Pollock PM, et al. Oncogene. 1995 Aug 17;11(4):663-8. Oncogene. 1995. PMID: 7651729
Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval.
Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF, Trent JM, Mann GJ, Hayward NK. Walker GJ, et al. Among authors: pollock pm. Genes Chromosomes Cancer. 2004 Sep;41(1):56-64. doi: 10.1002/gcc.20056. Genes Chromosomes Cancer. 2004. PMID: 15236317
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.
Pollock PM, Walker GJ, Glendening JM, Que Noy T, Bloch NC, Fountain JW, Hayward NK. Pollock PM, et al. Melanoma Res. 2002 Dec;12(6):565-75. doi: 10.1097/00008390-200212000-00006. Melanoma Res. 2002. PMID: 12459646
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin.
Cook AL, Pollock PM, Welch J, Walsh MD, Bowman RV, Baumann KC, Hayward NK, Leonard JH. Cook AL, et al. Among authors: pollock pm. Int J Cancer. 2001 Aug 1;93(3):361-7. doi: 10.1002/ijc.1352. Int J Cancer. 2001. PMID: 11433400
Mutation analysis of the CDKN2A promoter in Australian melanoma families.
Pollock PM, Stark MS, Palmer JM, Walters MK, Aitken JF, Martin NG, Hayward NK. Pollock PM, et al. Genes Chromosomes Cancer. 2001 Sep;32(1):89-94. doi: 10.1002/gcc.1170. Genes Chromosomes Cancer. 2001. PMID: 11477665
The genetics of cutaneous melanoma.
Pollock PM, Trent JM. Pollock PM, et al. Clin Lab Med. 2000 Dec;20(4):667-90. Clin Lab Med. 2000. PMID: 11221509 Review.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. Castellano M, et al. Among authors: pollock pm. Cancer Res. 1997 Nov 1;57(21):4868-75. Cancer Res. 1997. PMID: 9354451
The CDKN2A (p16) gene and human cancer.
Foulkes WD, Flanders TY, Pollock PM, Hayward NK. Foulkes WD, et al. Among authors: pollock pm. Mol Med. 1997 Jan;3(1):5-20. Mol Med. 1997. PMID: 9132280 Free PMC article. Review.
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM, Pearson JV, Hayward NK. Pollock PM, et al. Genes Chromosomes Cancer. 1996 Feb;15(2):77-88. doi: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0. Genes Chromosomes Cancer. 1996. PMID: 8834170 Review.
Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines.
Pollock PM, Hayward N. Pollock PM, et al. Melanoma Res. 2002 Apr;12(2):183-6. doi: 10.1097/00008390-200204000-00013. Melanoma Res. 2002. PMID: 11930117
66 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback